Source link : https://www.newshealth.biz/health-news/fda-expands-approval-of-rsv-vaccine-abrysvo-to-include-all-at-risk-adults/
The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in high-risk adults ages 18 to 59 years, Pfizer announced on Tuesday. The approval expands on the vaccine’s existing indications for the prevention of RSV-associated […]
Author : News Health
Publish date : 2024-10-23 16:29:54
Copyright for syndicated content belongs to the linked Source.